The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the challenges biotech firms face in maintaining growth momentum, Phathom Pharmaceuticals saw its shares tumble following a revision of its financial targets. The company cut its full-year 2026 revenue guidance by $20 million to a new range of $300 million to $325 million. This downward revision overshadowed a strong second quarter where the firm reported record net revenues of $74.3 million, marking an 88% increase compared to the same period last year.
According to analyst reports, the guidance cut triggered a massive sell-off, resulting in a single-day price drop of 22.42%. In response to the news, Needham lowered its price target for the stock to $22 from a previous $28. The sentiment was further pressured as law firm Levi & Korsinsky initiated an investigation notice, despite the company achieving operating profitability for the first time during the quarter and maintaining a cash balance of $182.5 million.
Looking ahead, investors are monitoring the stock's stability following high trading volumes that exceeded 7.61 million shares. While current price levels are unavailable at this snapshot, the market's focus remains on the company's ability to meet its revised annual targets. Key macroeconomic catalysts include the upcoming US CB Consumer Confidence data on July 28, 2026, which may influence broader sentiment across the consumer-facing healthcare sector.